Free tool
FAERS Monitor: Endari
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208587 or its brand name (Endari, L-Glutamine). Reports on generic versions are filed under their own applications.
Reports
4,606
Serious
2,873
62% of reports
Hospitalization
1,759
Death reported
128
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- sickle cell anaemia with crisis1,751
- product dose omission issue723
- pain281
- product dose omission272
- nausea241
- headache214
- hospitalisation212
- diarrhoea201
- abdominal pain upper160
- constipation152
- fatigue150
- drug dose omission132
- pain in extremity130
- emergency care128
- back pain127
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 18 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 10 |
| 2009 | 7 |
| 2010 | 18 |
| 2011 | 17 |
| 2012 | 32 |
| 2013 | 22 |
| 2014 | 28 |
| 2015 | 47 |
| 2016 | 88 |
| 2017 | 96 |
| 2018 | 781 |
| 2019 | 608 |
| 2020 | 439 |
| 2021 | 260 |
| 2022 | 352 |
| 2023 | 456 |
| 2024 | 707 |
| 2025 | 361 |
| 2026 | 232 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,553 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sickle cell anaemia with crisisSignal | 1,751 | 570.6 | 548.0 | 885,269 |
| emergency careSignal | 128 | 201.2 | 169.0 | 24,238 |
| product dose omissionSignal | 272 | 19.1 | 17.0 | 4,643 |
| product dose omission issueSignal | 723 | 11.3 | 10.5 | 6,822 |
| hospitalisationSignal | 212 | 6.3 | 5.5 | 947 |
| drug dose omissionSignal | 132 | 3.6 | 3.1 | 253 |
| abdominal pain upperSignal | 160 | 3.6 | 3.0 | 293 |
| constipationSignal | 152 | 3.2 | 2.7 | 228 |
| back painSignal | 127 | 2.5 | 2.1 | 114 |
| painSignal | 281 | 2.1 | 1.9 | 163 |
| pain in extremitySignal | 130 | 2.0 | 1.7 | 66 |
| headache | 214 | 1.6 | 1.4 | 44 |
| diarrhoea | 201 | 1.4 | 1.2 | 26 |
| nausea | 241 | 1.4 | 1.2 | 27 |
| fatigue | 150 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.